Compare AHCO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | CDNA |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2007 |
| Metric | AHCO | CDNA |
|---|---|---|
| Price | $10.84 | $37.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $13.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $3,244,857,000.00 | $48,324,000.00 |
| Revenue This Year | $9.00 | $16.01 |
| Revenue Next Year | $6.93 | $11.31 |
| P/E Ratio | ★ N/A | $752.20 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $8.51 | $11.26 |
| 52 Week High | $13.43 | $40.47 |
| Indicator | AHCO | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 72.16 |
| Support Level | $10.80 | $15.89 |
| Resistance Level | $12.87 | $40.47 |
| Average True Range (ATR) | 0.40 | 1.70 |
| MACD | 0.05 | 0.51 |
| Stochastic Oscillator | 55.61 | 77.26 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.